Is BPC-157 dosed by body weight?

There is no validated BPC-157 dose-per-kilogram rule for people. Weight-based figures seen online usually trace back to rat experiments, where researchers adjusted exposure among animals. Human studies have not established a per-kilogram schedule for under-the-skin BPC-157 injections, so the prescribed dose cannot be calculated from body weight alone.

Can a BPC-157 dosage calculator give me a safe dose?

No calculator can produce an evidence-based human BPC-157 dose from weight alone. Most calculators hide a direct conversion from rat studies and ignore differences in species, injection route, formulation, medical history and safety data. A licensed prescriber decides whether BPC-157 is appropriate and sets the actual prescription rather than relying on forum arithmetic.

What BPC-157 doses were used in rat studies?

Several foundational Achilles-tendon experiments reported 10 µg/kg, 10 ng/kg and 10 pg/kg, given into rats' abdominal cavities once daily. A July 2026 rat study used 10 µg/kg daily for four weeks. These are descriptions of controlled animal experiments after surgically created injuries, not dose recommendations or a schedule for people.

Does a heavier person need more BPC-157?

That has not been established. Some medicines are adjusted for weight, but others use fixed doses or depend more on organ function, route and treatment goal. No human BPC-157 trial has shown that a heavier adult needs proportionally more, or that direct weight scaling produces a safer or more useful exposure.

How does a provider choose a BPC-157 dose?

The provider considers the reason for treatment, exact formulation and route, medical history, current medicines, prior reactions and the plan for follow-up. Body size may be one detail, but there is no validated formula that makes it the deciding factor. The final amount and schedule belong to the individual prescription.

What is BPC-157's FDA status?

BPC-157 is not FDA-approved, and the small human reports available have not established a standard dose for injury recovery. FDA review status does not replace an individual medical decision: a licensed provider may still prescribe a compounded formulation, and that decision is between the patient and the doctor.

BPC-157 Dosage by Body Weight: No Human Formula

There is no evidence-based BPC-157 dosage by body weight for people. If a website asks for pounds or kilograms and returns a microgram amount, it is not applying a human dosing standard. It is usually turning an animal-study number into a human answer with simple arithmetic. No published human trial has established a per-kilogram schedule for BPC-157 injections.

Body size can matter when a doctor chooses a medicine. Here, the evidence needed to say how it matters is missing. A prescriber sets the actual dose, if BPC-157 is appropriate at all, using how the medicine will be given, the formulation—the exact preparation—the reason for treatment, medical history and safety picture, not a calculator alone.

Why BPC-157 dosage by body weight appears online

BPC-157 is a peptide, a short chain of amino acids. Many of its best-known experiments report dose in micrograms per kilogram, written µg/kg; one microgram is one millionth of a gram. In an animal experiment, that unit lets researchers give rats of different sizes comparable exposure. It does not create a human prescription rule.

A 2003 Achilles-tendon study gave rats 10 µg/kg, 10 ng/kg or 10 pg/kg once daily into the abdominal cavity after researchers cut the tendon. A 2006 tendon-to-bone study used the same three levels in rats after surgical detachment. Intraperitoneal means injected into the abdominal cavity, which is not the under-the-skin route usually discussed in clinics.

Those papers answer a narrow laboratory question: what happened in rats under those exact conditions. They do not show which amount is useful, tolerable or safe for a person, and they do not show that a heavier adult needs proportionally more.

Fresh 2026 evidence is still animal evidence

As of September 6, 2026, the day this article was written, the newest direct dose study was a July 23 experiment in 32 male rats, with eight animals in each group. Researchers used 10 µg/kg of BPC-157 each day into the abdominal cavity for four weeks after Achilles-tendon repair. The BPC-157 group's tissue scores and maximum load—the force its repaired tendon could withstand—did not show a clear difference from controls, and the authors said dose optimization was still needed.

The FDA's materials for a public committee meeting held the same day offered a second reality check. The agency found five small clinical studies but no human study using BPC-157 orally, under the skin, nasally or through the skin. The meeting concerned whether BPC-157 ingredients should appear on the federal list used for patient-specific pharmacy compounding; it did not create a human dose.

The new rat study also tested BPC-157 with TB-500, the pairing often called Wolverine. The combination showed no added advantage over either peptide alone in that rat model. It does not establish a human amount for either ingredient or the blend. The BPC-157 versus TB-500 comparison explains why the two compounds are not interchangeable.

Why rat arithmetic is not allometric scaling

Multiplying a rat's µg/kg figure by a person's weight is direct scaling. It assumes the two species absorb, distribute, break down and clear BPC-157 alike. That assumption has not been shown.

Allometric scaling—a research method that adjusts between species using size and physiology—is more involved. Even that method is meant to help design a cautious starting exposure for a first human trial, not to publish a treatment schedule. A review of dose translation warned that surface-area conversions can be mistaken for an active human dose and said proper translation needs physiology, pharmacokinetics and toxicology (Blanchard and Smoliga, FASEB Journal 2015). Pharmacokinetics means how a substance moves through and leaves the body; toxicology is the study of harmful effects.

The FDA's starting-dose guidance begins with a no-observed-adverse-effect level—the highest tested animal exposure without a measured harmful effect—and then applies a safety factor. The popular BPC-157 number comes from experiments looking for an effect, not from that full safety process. Route matters too: a result after an abdominal-cavity injection cannot simply be carried over to an under-the-skin injection.

The human evidence does not supply a formula

The five human reports FDA found do not all answer the same question. They involved rectal enemas, injections into a knee joint or bladder, and infusion into a vein. None established a weight-based under-the-skin schedule for injury recovery.

One older first-stage safety meeting abstract tested several weight-based enema levels for eight days. That was a short tolerability study, not a dose-finding trial that established an effective injection schedule. Across the human reports, FDA described the doses as exploratory and the safety information as limited.

This is the gap a BPC-157 dose calculator hides. A number can look precise while resting on the wrong species, a different route and an outcome that was never tested in people.

How a provider actually decides

A real dosing decision starts with the person rather than a multiplication table. The provider considers what is being treated, the exact prescribed formulation, route, other medicines, health history and whether the expected follow-up can catch a problem early. Body size may be one detail, but there is no validated BPC-157 rule that makes it the deciding detail.

The unknowns matter. Human safety data are sparse, and animal studies have not settled a dose-response relationship—whether a larger exposure produces a different effect. The BPC-157 side-effects guide covers the known and uncertain risks, while the BPC-157 half-life explainer separates how quickly the peptide is cleared from how often it might be prescribed.

BPC-157 is not FDA-approved. A licensed provider may still prescribe a compounded formulation, meaning one prepared by a pharmacy for an individual prescription; that decision is between the patient and the doctor. At Promise, a licensed provider reviews every request, and not everyone qualifies.

The useful details at a visit

The useful inputs are the actual diagnosis or concern, when it began, prior treatment, current medicines, allergies, medical conditions and any previous reaction to an injectable. The prescriber also needs to know the exact product and route being considered. A body-weight number without that context cannot answer the dosing question safely.

The honest answer may feel less satisfying than a calculator: there is no conversion table to hand over. But that uncertainty is exactly why the dose belongs inside a clinical relationship, with a specific prescription and follow-up.